MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT

Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Dec 19, 2024

Keywords

ClinConnect Summary

This clinical trial is comparing two different methods for diagnosing gastrointestinal stromal tumors (GISTs) in the stomach, which are a type of submucosal tumor (SMT). The two methods being studied are EUS-FNA, a technique that uses ultrasound to guide a needle to collect tissue samples, and MCB, a newer method that allows doctors to take a more precise tissue sample during an endoscopy. The goal of the study is to see which method gives better results in identifying these tumors, which could help improve treatment options and outcomes for patients.

To be eligible for this trial, participants need to have a gastric submucosal tumor that is at least 15mm in size. Unfortunately, individuals with certain conditions, such as those who have had previous upper gastrointestinal surgery, pregnant women, or those with certain blood clotting issues, cannot participate. If someone joins the trial, they can expect to undergo one of the two biopsy techniques to help determine the nature of their tumor. This research aims to enhance diagnostic accuracy and ultimately improve the prognosis for patients with these types of tumors.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Endoscopic evaluation considers gastric submucosal tumors (SMTs) with a diameter of ≥ 15mm
• Exclusion Criteria:
• • Endoscopic non bulging lesions.
• • The upper gastrointestinal lesions measured by Endoscopic Ultrasonography(EUS) are less than 15 mm.
• • Lesions that do not require tissue collection (such as lipomas, varicose veins)
• • Patients with cystic lesions
• • The patient has uncorrectable coagulation dysfunction (International Normalized Ratio (INR)\>1.5 or platelet count\<50x109)
• • Patients with portal hypertension
• • Patients with a history of upper gastrointestinal surgery
• • Pregnant women
• • Patients who refuse to participate in this clinical trial